Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SMMT
stocks logo

SMMT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.020
-74.39%
--
--
-0.057
-36.62%
--
--
-0.060
-92.08%
Estimates Revision
The market is revising Downward the revenue expectations for Summit Therapeutics Inc. (SMMT) for FY2025, with the revenue forecasts being adjusted by -1.85% over the past three months. During the same period, the stock price has changed by -27.60%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.85%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.82%
In Past 3 Month
Stock Price
Go Down
down Image
-27.60%
In Past 3 Month
Wall Street analysts forecast SMMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMMT is 30.82 USD with a low forecast of 13.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast SMMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMMT is 30.82 USD with a low forecast of 13.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
2 Hold
3 Sell
Moderate Buy
Current: 18.810
sliders
Low
13.00
Averages
30.82
High
40.00
Current: 18.810
sliders
Low
13.00
Averages
30.82
High
40.00
Wolfe Research
Kalpit Patel
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Summit Therapeutics with a Peer Perform rating and no price target. The firm's analysis suggests the Harmoni-2 may not show an overall survival benefit, the analyst tells investors.
Barclays
Underweight
maintain
$13 -> $16
2025-10-21
Reason
Barclays
Price Target
$13 -> $16
2025-10-21
maintain
Underweight
Reason
Barclays raised the firm's price target on Summit Therapeutics to $16 from $13 and keeps an Underweight rating on the shares. The firm updated the company's model to include colorectal cancer but says "key questions remain."
H.C. Wainwright
Buy
downgrade
$50 -> $40
2025-10-21
Reason
H.C. Wainwright
Price Target
$50 -> $40
2025-10-21
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Summit Therapeutics to $40 from $50 and keeps a Buy rating on the shares. The firm cites "conservative" second-line EGFRmut approval odds and higher spending for the target cut. However, it recommends buying Summit shares ahead of HARMONi-2's next survival analysis.
Citi
Buy
maintain
$35 -> $40
2025-10-20
Reason
Citi
Price Target
$35 -> $40
2025-10-20
maintain
Buy
Reason
Citi raised the firm's price target on Summit Therapeutics to $40 from $35 and keeps a Buy rating on the shares. The firm has higher conviction in ivonescimab following the HARMONi-6 data.
Clear Street
Buy
downgrade
$33 -> $32
2025-10-20
Reason
Clear Street
Price Target
$33 -> $32
2025-10-20
downgrade
Buy
Reason
Clear Street lowered the firm's price target on Summit Therapeutics to $32 from $33 and keeps a Buy rating on the shares. The stock is trading down after several updates over the weekend, including details of the HARMONi-6 study in which ivonescimab beat tislelizumab head-to-head in squamous non-small cell lung cancer and the announcement of a planned Phase 3 study in first-line colorectal cancer, the analyst tells investors in a research note. Clear Street still believes that ivonescimab has consistently outperformed PD-1 treatments, which are standard-of-care in solid tumor indications. It cites an increased projected share count for the target cut.
Citi
Buy
maintain
$35
2025-09-25
Reason
Citi
Price Target
$35
2025-09-25
maintain
Buy
Reason
Citi added a "30-day upside catalyst watch" on shares of Dummit Therapeutics while keeping a Buy rating on the name with a $35 price target. The firm sees the stock moving higher on HARMONi-6 presentation scheduled for October 19.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Summit Therapeutics Inc (SMMT.O) is -100.24, compared to its 5-year average forward P/E of -20.78. For a more detailed relative valuation and DCF analysis to assess Summit Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-20.78
Current PE
-100.24
Overvalued PE
6.59
Undervalued PE
-48.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
6.97
Undervalued EV/EBITDA
-35.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
358.22
Current PS
0.00
Overvalued PS
941.00
Undervalued PS
-224.56
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SMMT News & Events

Events Timeline

(ET)
2025-12-04
14:00:00
Polyrizon Sees 7,453.25% Surge in Search Activity
select
2025-12-01 (ET)
2025-12-01
03:52:00
Sezzle's Short Interest Hits Record High of 24.2%
select
link
2025-10-30 (ET)
2025-10-30
11:03:31
Akeso Reveals Findings from OS Analysis of Phase III HARMONi-A Study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03NASDAQ.COM
PinnedHold Off on Purchasing Summit Therapeutics Until This Major Event Occurs

  • FDA Approval Plans: Summit Therapeutics plans to file a Biologics License Application (BLA) for its drug ivonescimab in combination with chemotherapy by the end of 2025, despite previous FDA guidance requiring a statistically significant overall survival benefit that was not met in clinical trials.

  • Stock Volatility: The outcome of the FDA's decision on the BLA is expected to significantly impact Summit's stock price, with potential for a sharp increase if accepted or a further decline if rejected.

  • Future Studies: Regardless of the FDA's decision on the BLA, Summit has plans to report data from another phase 3 study of ivonescimab combined with chemotherapy for a different indication in 2026, which could lead to another BLA submission.

  • Investment Caution: Investors are advised to be cautious and consider waiting for the FDA's decision before investing in Summit Therapeutics, as the stock's future is highly dependent on this binary outcome.

[object Object]
Preview
4.5
12-04Benzinga
Small Cap Stocks Surge as Natural Gas Prices Reach Three-Year Highs: Market Movers for Wednesday

  • Market Performance: Small-cap stocks surged over 1% as expectations for a Federal Reserve rate cut increased following disappointing private employment data, while large-cap indices like the S&P 500 and Nasdaq 100 saw minimal gains.

  • Employment Data Impact: The ADP report indicated a loss of 32,000 jobs in November, contrary to expectations, suggesting a cooling labor market and contributing to the anticipation of a rate cut.

  • Sector Highlights: Energy stocks outperformed with rising oil and natural gas prices, while Microchip Technology saw a significant stock increase after raising its earnings outlook, contrasting with Netflix's decline due to regulatory scrutiny.

  • Cryptocurrency Movement: Bitcoin rose 1.3% to $92,500, aiming for a second consecutive gain after a recent selloff, reflecting ongoing volatility in the crypto market.

[object Object]
Preview
9.5
11-28NASDAQ.COM
Transcript of Summit SMMT Earnings Call for Q3 2025
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Summit Therapeutics Inc (SMMT) stock price today?

The current price of SMMT is 18.81 USD — it has increased 2.4 % in the last trading day.

arrow icon

What is Summit Therapeutics Inc (SMMT)'s business?

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

arrow icon

What is the price predicton of SMMT Stock?

Wall Street analysts forecast SMMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMMT is 30.82 USD with a low forecast of 13.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Summit Therapeutics Inc (SMMT)'s revenue for the last quarter?

Summit Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Summit Therapeutics Inc (SMMT)'s earnings per share (EPS) for the last quarter?

Summit Therapeutics Inc. EPS for the last quarter amounts to -0.31 USD, increased 287.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Summit Therapeutics Inc (SMMT)'s fundamentals?

The market is revising Downward the revenue expectations for Summit Therapeutics Inc. (SMMT) for FY2025, with the revenue forecasts being adjusted by -1.85% over the past three months. During the same period, the stock price has changed by -27.60%.
arrow icon

How many employees does Summit Therapeutics Inc (SMMT). have?

Summit Therapeutics Inc (SMMT) has 159 emplpoyees as of December 05 2025.

arrow icon

What is Summit Therapeutics Inc (SMMT) market cap?

Today SMMT has the market capitalization of 14.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free